Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.
about
Polypharmacy for schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.Interventions for the metabolic syndrome in schizophrenia: a reviewObesity in bipolar disorder: an overview.Treatment of clozapine-associated weight gain: a systematic review.Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Managing comorbid obesity and depression through clinical pharmacotherapies.Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?
P2860
Q33634660-6E912E08-F590-4220-8BF1-1124F23F99F5Q34315836-C707319C-F121-4326-9AA1-862ABD8DE82CQ36034676-34A3386C-9423-4581-9AA3-9570130BB846Q36377890-7705B789-5987-41FA-B0DE-6FFD6797547EQ36401248-DB27F1D6-4EDD-41D9-B2ED-2A6CCF2E8FE8Q38035727-4A30C358-0C04-48E8-998F-D611C769539AQ38334922-68CFB63B-4DBD-4F5B-ABC8-3CC029C7C6CEQ38352080-02561884-8AAE-4A99-9AC0-27E09A0A8952Q38826206-410C6F62-4DC2-4C9A-8F11-37ED4A4D66FCQ38859885-7EBC447D-B855-411E-9212-15599904E005Q40082921-832ABAB5-4E57-458F-961F-68C9E66AC305Q50973671-DB85334D-25B1-4501-A140-F45CFA9A13FC
P2860
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Orlistat in clozapine- or olan ...... a randomized controlled trial.
@en
type
label
Orlistat in clozapine- or olan ...... a randomized controlled trial.
@en
prefLabel
Orlistat in clozapine- or olan ...... a randomized controlled trial.
@en
P2093
P50
P356
P1476
Orlistat in clozapine- or olan ...... a randomized controlled trial.
@en
P2093
Evgueni Tchoukhine
Hanna Putkonen
Jan-Henry Stenberg
Markku Eronen
Mirjam Raidma
Pirjo Takala
Viacheslav Terevnikov
P304
P356
10.4088/JCP.09M05283YEL
P577
2010-08-24T00:00:00Z